| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Epoxiconazole targets lanosterol 14α-demethylase (CYP51), a cytochrome P450 enzyme involved in ergosterol biosynthesis. It acts as a competitive inhibitor of CYP51, blocking the conversion of lanosterol to ergosterol. This inhibition disrupts fungal cell membrane integrity and function, leading to fungal growth inhibition and cell death.
|
|---|---|
| ln Vitro |
In vitro, Epoxiconazole inhibits lanosterol 14α-demethylase (CYP51) activity, blocking ergosterol biosynthesis in fungal cells. The compound demonstrates broad-spectrum antifungal activity against various plant pathogenic fungi. Specific IC50 values for CYP51 inhibition are available from enzymatic assays. Epoxiconazole shows potent activity against Ascomycetes, Basidiomycetes, and Deuteromycetes fungi.
|
| ln Vivo |
In vivo, Epoxiconazole is used as a broad-spectrum agricultural fungicide for the control of fungal diseases in cereals, fruits, and vegetables. It is applied as a foliar spray or seed treatment. The compound provides systemic and protective activity against a wide range of fungal pathogens, including Septoria, Fusarium, and Rhynchosporium species.
|
| Enzyme Assay |
The in vitro enzyme activity assay for Epoxiconazole involves measuring its inhibitory effect on lanosterol 14α-demethylase (CYP51) activity. Recombinant fungal CYP51 enzyme is incubated with varying concentrations of Epoxiconazole and its substrate, lanosterol, in the presence of NADPH. The extent of demethylation is measured by HPLC or mass spectrometry. The IC50 for CYP51 inhibition is determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for Epoxiconazole involve treating cultured fungal cells with varying concentrations of the compound. Fungal growth is assessed by measuring optical density or colony formation. Ergosterol content in fungal cell membranes is measured by HPLC or spectrophotometry. The compound's antifungal activity is evaluated by comparing growth inhibition and ergosterol reduction to untreated controls.
|
| Animal Protocol |
In vivo animal experiments for Epoxiconazole typically use plant models of fungal infection rather than animals. Infected plants are treated with Epoxiconazole via foliar spray or seed treatment at various doses. Disease severity is assessed by measuring lesion size or fungal biomass. The compound's protective and curative activities are evaluated. As an agricultural fungicide, Epoxiconazole is not typically tested in animal models for efficacy.
|
| ADME/Pharmacokinetics |
Epoxiconazole has a molecular weight of 329.76 (C17H13ClF N3O). As a triazole fungicide, it is absorbed by plants and provides systemic protection. The compound is metabolized in plants and soil. In mammals, Epoxiconazole is metabolized by cytochrome P450 enzymes and excreted via urine and feces. Specific PK parameters in humans are not extensively documented.
|
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (Rat) > 5,300 mg/m3 Epoxiconazole has been extensively studied for its toxicological profile as an agricultural chemical. Potential adverse effects in mammals may include hepatotoxicity, reproductive toxicity, and endocrine disruption due to CYP51 inhibition. The compound is classified as a potential endocrine disruptor. Complete toxicology data are available from regulatory submissions for agricultural use. |
| References | |
| Additional Infomation |
According to the U.S. Environmental Protection Agency (EPA), epoxazole may be carcinogenic. (2S,3R)-epoxazole is the (2S,3R)-stereomer of 1-{3-(2-chlorophenyl)-2-(4-fluorophenyl)epoxyethylene-2-yl]methyl}-1H-1,2,4-triazole. It is the enantiomer of (2R,3S)-epoxazole. Opal is a mineral with the chemical formula SiO2·nH2O. Its symbol in the International Mineralogical Association (IMA) is Opl.
Epoxiconazole (CAS#: 133855-98-8) is a broad-spectrum triazole fungicide that inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol biosynthesis in fungal cell membranes. It is widely used in agriculture for the control of fungal diseases in cereals, fruits, and vegetables. Epoxiconazole provides systemic and protective activity against a wide range of fungal pathogens. It is not used as a drug and is not approved for human therapeutic use. |
| Molecular Formula |
C17H13CLFN3O
|
|---|---|
| Molecular Weight |
329.75
|
| Exact Mass |
329.073
|
| CAS # |
133855-98-8
|
| Related CAS # |
106325-08-0;
|
| PubChem CID |
107901
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
463.1±55.0 °C at 760 mmHg
|
| Melting Point |
125°C (lit.)
|
| Flash Point |
233.9±31.5 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.659
|
| LogP |
3.44
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
421
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC=C(C(=C1)[C@@H]2[C@@](O2)(CN3C=NC=N3)C4=CC=C(C=C4)F)Cl
|
| InChi Key |
ZMYFCFLJBGAQRS-IAGOWNOFSA-N
|
| InChi Code |
InChI=1S/C17H13ClFN3O/c18-15-4-2-1-3-14(15)16-17(23-16,9-22-11-20-10-21-22)12-5-7-13(19)8-6-12/h1-8,10-11,16H,9H2/t16-,17-/m1/s1
|
| Chemical Name |
1-[[(2S,3R)-3-(2-chlorophenyl)-2-(4-fluorophenyl)oxiran-2-yl]methyl]-1,2,4-triazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~303.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0326 mL | 15.1630 mL | 30.3260 mL | |
| 5 mM | 0.6065 mL | 3.0326 mL | 6.0652 mL | |
| 10 mM | 0.3033 mL | 1.5163 mL | 3.0326 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
